<DOC>
	<DOC>NCT00281541</DOC>
	<brief_summary>A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.</brief_summary>
	<brief_title>A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma</brief_title>
	<detailed_description>A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma Life expectancy &gt;12 weeks History of other malignancy in the last 5 years Major surgery within the past 21 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Disease Management</keyword>
	<keyword>Treatment</keyword>
	<keyword>Safety</keyword>
	<keyword>Malignant Melanoma</keyword>
</DOC>